

## Drugs & Diagnostics for Tropical Diseases 9909 Huennekens St. | Suite 100 | San Diego | 92121 Phone: 858-614-6454, <u>www.ddtd.org</u>


**NSF International** 

ISO-13485 Certification #

C0448681

## **Certificate of Analysis**

	Detail		
Product Name	Buruli Ulcer RDT		
Part No, if available			
Packaging Information	A sealed metalized pouch with 100 individually sealed Buruli Ulcer RDT cassettes, a glass vial with 5 doses of lyophilized magnetic nanoparticles Mag-NS-JD5.1, a dropper vial with chase buffer, all stored at 4°C; 10 μM mycolactone in ethanol for positive control stored at -20 °C.		
Quantity	100 cassettes x5 , 20 glass vials with lyophilized Mag-NS-JD5.1 x 5, 2 droppers with 4 ml chase buffer x5, 4 ampoules with 60 ul of 10 μM mycolactone (7ng/μL) in ethanol.		
Lot Number	Mag-NS-JD5.1 Lot# MS-2021-272 (lyophilized) NC Strips Lot# MS-2021-269 Assembled cassettes Lot# MS-2021-272 Running buffer Lot# MS-2021-274		
Manufacturing Date	April 2021		
Expiration Date	October 2021		
Storage Condition	4 °C		
Test Method	7 ng mycolactone in 50 μL simulated exudate extracted with 400 μL 100 mM TEA buffer or di-H2O, incubated with 50 μL of reconstituted Mag-NS-JD5.1 for 25 min, Mag-NS-JD5.1 were concentrated on magnetic rack for 10 min, resuspended with 2 drops of running buffer, transferred to the sample port of the cassette, read in 30 min.		
Test Specification	3 shades difference for the test line intensity between positive and negative sample or 0.05 absorbance units by Leelu reads		
Test Results	The difference in test line intensity between positive and negative sample: 3-2.5 shades 0.06-0.37 absorbance by Leelu		
Approved or Rejected			
	Disclosure		
Copies of the actual testing	related documents are provided to the customers upon request.		



The undersign confirms that this product meets or exceeds all specifications set forth by the customer in the order.

Name	Marina 7. Silvin
Designation	CEO/Quality Manager/Sr. Scientist
Signature/Date	04/30/2021

А

В

Document Control					
Action	Date	Signature	Author/Reviewer/Approver		
Approved					
Implemented			Dr. Marco Biamonte, CEO		
Amendment/Change					